Alexion’s CEO search is over. The Connecticut biotech, which bade its skipper farewell late last year, is bringing former Baxalta chief Ludwig Hantson into the fold.
Hantson will take the reins from David Brennan, who stepped in as interim CEO after David Hallal made his exit last December. Brennan will remain on Alexion’s board, which expects to appoint him chairman at the company’s mid-May annual meeting, Alexion said.
All eyes will be on the newcomer CEO, who will be tasked with helping Alexion move on after an investigation that found that, to hit financial targets, former execs pressed staffers to get customers to place their orders of lead med Soliris earlier than they would have otherwise. During that probe, both Hallal and then-CFO Vikas Sinha left the company, with one source telling CNBC that the pair had lost the confidence of Alexion’s board.
Meanwhile, Hantson’s experience in the rare-disease field will come in handy at Alexion, whose marketed products are used to treat orphan diseases such as paroxysmal nocturnal hemoglobinuria and lysosomal acid lipase deficiency. Baxalta’s hemophilia prowess is what drew rare-disease drugmaker Shire’s attention, and its 2016 buyout of the Baxter spinoff put Hantson out of a job.
He’ll need to lean on that know-how early, with plenty of near-term events on Alexion’s horizon. Among them: regulatory decisions in the U.S. and EU for Soliris in refractory generalized myasthenia gravis, an indication that could kick in about $200 million in additional sales by 2020, Barclays analyst Geoff Meacham has predicted.
On his resume, Hantson has more than the stint at short-lived Baxalta, which stood on its own for less than a year before the $32 billion Shire deal closed. He held a number of roles with Novartis—including CEO of Novartis’ North American pharma division and CEO of Novartis Europe—as part of a decade-long tenure at the Swiss pharma giant.
By Carly Helfand
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
